Department of Geriatrics, West China Fourth Hospital, Sichuan University, Chengdu, China.
Xindu Hospital of Traditional Chinese Medicine, Chengdu, China.
Brain Behav. 2019 Feb;9(2):e01215. doi: 10.1002/brb3.1215. Epub 2019 Jan 18.
CGRP monoclonal antibody (mAb) is a promising preventive treatment for episodic migraine and has been approved by US FDA recently. But the treatments for chronic migraine are rare. Therefore, we performed meta-analysis to assess the efficacy and safety of CGRP mAbs in preventing chronic migraine.
Database including Cochrane Library and PubMed were systematically searched for randomized controlled trials (RCTs) which are about CGRP mAb in preventing treatment of chronic migraine. Evaluating the bias and quality of RCTs was carried out according to the Cochrane collaboration's tool for assessing risk of bias. The data analysis was carried out by reviewer manager 5.2.
Totally, 6 articles enrolled in the present meta-analysis, including 4 independent clinical trials and 3,166 patients. After pooled analysis, it indicated that CGRP mAb improved 50% responder rate (OR = 2.42, 95% CI = [2.04, 2.87], I = 0%, p < 0.00001) and 75% responder rate (OR = 1.95, 95% CI = [1.30, 2.91], I = 0%, p = 0.001), as compared with placebo. And there was no difference in incidence of adverse events between CGRP mAb group and placebo group except incidence of injection site discomfort.
CGRP mAb is an effective and safety preventive treatment for chronic migraine.
降钙素基因相关肽（CGRP）单克隆抗体（mAb）是一种有前途的发作性偏头痛预防治疗药物，最近已获得美国食品和药物管理局（FDA）的批准。但慢性偏头痛的治疗方法却很少。因此，我们进行了荟萃分析，以评估 CGRP mAb 预防慢性偏头痛的疗效和安全性。
系统检索 Cochrane 图书馆和 PubMed 数据库，以评估 CGRP mAb 预防慢性偏头痛的疗效和安全性。根据 Cochrane 协作组评估偏倚风险的工具，评估 RCT 的偏倚和质量。数据采用 Review Manager 5.2 软件进行分析。
共纳入 6 篇文章，包括 4 项独立的临床试验和 3166 例患者。荟萃分析结果表明，CGRP mAb 可提高 50%应答率（OR=2.42，95%CI=[2.04, 2.87]，I²=0%，p<0.00001）和 75%应答率（OR=1.95，95%CI=[1.30, 2.91]，I²=0%，p=0.001），与安慰剂相比。除注射部位不适外，CGRP mAb 组与安慰剂组的不良反应发生率无差异。
CGRP mAb 是一种有效且安全的慢性偏头痛预防治疗药物。
